THE USE OF HORMONE REPLACEMENT THERAPY IN SLOVENIAN WOMEN BEFORE THE FIRST DIAGNOSIS OF BREAST CANCER
Abstract
Background. The aim of our retrospective study was to collect and compare data on hormone replacement therapy prescription in Slovenian women before the first diagnosis of breast cancer and the control group of randomly selected healthy women matched by age.
Patients and methods. We carried out a cross-sectional, case-control study and enrolled 1408 women aged between 50 and 69 years. They were invited to participate via a personal letter and asked to complete written questionnaire. Besides questions regarding drug intake of sex hormones and general information, questionnaire contained questions that provide reproductive data and family history of cancer. We used the independent t-test to compare the values of the means between the two groups and the chi-square statistic to determine an association for categorical data between groups.
Results. In our study, significantly more women in the control group were using HRT. Although, there was not statistically significant difference in the proportion of women between the control and the experimental group using HRT for more than 5 years. There was higher proportion of women in the experimental group receiving combined HRT, but the difference was not statistically significant. Furthermore, there was also significantly higher proportion of women in the experimental group receiving systemic HRT and significantly higher proportion of women in the control group receiving local HRT preparations.
Conclusions. HRT is still the most efficient way to treat debilitating menopausal symptoms. Although the linkage between the use of HRT and increased breast cancer risk is physiologically plausible, our preliminary results show that observable risk is moderate.
Downloads
References
Primic Žakelj M, Zadnik V. Epidemiologija raka dojk v svetu in
v Sloveniji. Radiol Oncol 2004; 38 Suppl 1: 1–7.
Incidenca raka v Sloveniji 2005. Ljubljana: Onkološki inštitut,
Register raka za Slovenijo; 2008.
Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer.
Cancer Surv 1993; 18: 95–113.
Travis C, Key TJ. Oestrogen exposure and breast cancer risk.
Breast Cancer Res 2003; 5: 239–47.
Kendall A, Folkerd EJ, Dowsett M. Influences on circulating oestrogens
in postmenopausal women: Relationship with breast
cancer. J Steroid Biochem Mol Biol 2007; 103: 99–109.
Pike MC, Spicer DV, Dahmoush L, Press MF. Oestrogens, progestogens,
normal breast cell proliferation, and breast cancer risk.
Epidemiol Rev 1993; 15: 17–35.
Yager JD. Endogenous oestrogens as carcinogens through metabolic
activation. J Natl Cancer Inst Monogr 2000; 27: 67–73.
Uršič-Vrščaj M. Hormonsko nadomestno zdravljenje in rak. Zdrav
Vestn 2003; 72: Suppl 2: 15–8.
Collaborative group on hormonal factors in breast cancer.
Breast cancer and hormone replacement therapy: collaborative
reanalysis of data from 51 epidemiological studies of 52705
women with breast cancer and 108411 women without breast
cancer. Lancet 1997; 350: 1047–59.
McPherson K, Steel C M, Dixon J M. Breast cancer-epidemiology,
risk factors, and genetics. BMJ 2000; 321: 624–8.
Writing group for the Women´s Health Initiative Investigators.
Risk and benefits of estrogen plus progestin in healthy
postmenopausal women: principal results from the Women´s
Health Initiative randomized controlled trial. JAMA 2002; 288:
–33.
Pines A, Sturdee D W, Birkhauser M H, de Villiers T, Naftolin F,
Gompel A, et al. HRT in early menopause: scientific evidence and
common perceptions. Summery of the First IMS Global Summit
on menopause-related issues. Zurich, March 29–30, 2008.
Skouby S O, Al-Azzawi F, Barlow D, Gompel A, Samsioe G,
Graziottin A, et al. Climacteric medicine: European Menopause
and Andropause Society (EMAS) 2004/2005 position statements
on peri- and postmenopausal hormone replacement therapy.
Maturitas 2005; 51: 8–14.
Key T J, Verkasalo P K, Banks E. Epidemiology of breast cancer.
Lancet Oncol 2001; 2: 133–40.
Uršič-Vrščaj M, Baškovič M, Bebar S, Djurišić A, Stržinar V, Vakselj
A. Hormonsko nadomestno zdravljenje in rak dojk – novosti in
priporočila. Zdrav Vestn 2008; 77 Suppl 3: 55–8.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
